{"id":3846,"date":"2018-12-17T07:45:00","date_gmt":"2018-12-17T07:45:00","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/"},"modified":"2018-12-17T07:45:00","modified_gmt":"2018-12-17T07:45:00","slug":"nanexa-ingar-avtal-med-varldsledande-animal-health-bolag","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/","title":{"rendered":"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag"},"content":{"rendered":"
\n

<\/strong><\/span><\/p>\n<\/div>\n

Nanexa skrev sent fredag kv\u00e4ll ett kommersiellt utv\u00e4rderingsavtal, ett s\u00e5 kallat\u201dMaterial transfer and feasibility study agreement\u201d, med ett v\u00e4rldsledande globalt animal health-bolag.<\/span><\/p>\n

Bolaget som har sitt huvudkontor i USA kommer inom ramen f\u00f6r avtalet utv\u00e4rdera PharmaShell\u00ae\u00a0f\u00f6r en specifik kombinationsprodukt. Det \u00e4r PharmaShells\u00aeegenskaper som g\u00f6r det m\u00f6jligt att skapa riktigt l\u00e5nga dep\u00e5produkter som efterfr\u00e5gats av det amerikanska bolaget.<\/span><\/p>\n

Avtalet inneb\u00e4r att Nanexa ska bel\u00e4gga bolagets aktiva substanser med PharmaShell\u00ae\u00a0och att de i sin tur utv\u00e4rderar effekten av detta i relevanta modeller f\u00f6r deras t\u00e4nkta produktutveckling. Produkten som de siktar p\u00e5 att utveckla med PharmaShell\u00ae\u00a0\u00e4r f\u00f6r en betydande indikation och planeras att anv\u00e4ndas f\u00f6r flera djurslag. Den globala marknaden f\u00f6r animal health v\u00e4rderas till 42.2 miljarder USD med en \u00e5rlig tillv\u00e4xt p\u00e5 5,5% enligt Grand View Research, June 2018.<\/span><\/p>\n

Animal-health bolaget st\u00e5r f\u00f6r alla kostnader f\u00f6r utv\u00e4rdering och Nanexa erh\u00e5ller en avtalad mindre ers\u00e4ttning vid leverans av belagt material.<\/span><\/p>\n

F\u00f6retagets VD David Westberg kommenterar:<\/span><\/p>\n

\u201d\u00a0Jag \u00e4r mycket n\u00f6jd \u00f6ver att vi nu har tecknat ett kommersiellt avtal med ett stort globalt f\u00f6retag inom den attraktiva animal health-branschen. Det \u00e4r ett stort steg i helt r\u00e4tt riktning f\u00f6r Nanexa.\u201d<\/span><\/p>\n

F\u00f6r mer information kontakta:
David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0Telefon: 0709 -42 83 03
E-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/p>\n

Denna information \u00e4r s\u00e5dan information som Nanexa AB \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 17 december, 2018.<\/span><\/p>\n

Om Nanexa AB (publ)
Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

\n

Bifogade filer<\/strong><\/p>\n\n

L\u00e4s som pdf<\/a><\/p>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n

Nanexa skrev sent fredag kv\u00e4ll ett kommersiellt utv\u00e4rderingsavtal, ett s\u00e5 kallat\u201dMaterial transfer and feasibility study agreement\u201d, med ett v\u00e4rldsledande globalt animal health-bolag.<\/p>\n

Bolaget som har sitt huvudkontor i USA kommer inom ramen f\u00f6r avtalet utv\u00e4rdera PharmaShell\u00ae\u00a0f\u00f6r en specifik kombinationsprodukt.<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3846","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa skrev sent fredag kv\u00e4ll ett kommersiellt utv\u00e4rderingsavtal, ett s\u00e5 kallat\u201dMaterial transfer and feasibility study agreement\u201d, med ett v\u00e4rldsledande globalt animal health-bolag. Bolaget som har sitt huvudkontor i USA kommer inom ramen f\u00f6r avtalet utv\u00e4rdera PharmaShell\u00ae\u00a0f\u00f6r en specifik kombinationsprodukt.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\\\/\",\"name\":\"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2018-12-17T07:45:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag - Nanexa AB","og_description":"Nanexa skrev sent fredag kv\u00e4ll ett kommersiellt utv\u00e4rderingsavtal, ett s\u00e5 kallat\u201dMaterial transfer and feasibility study agreement\u201d, med ett v\u00e4rldsledande globalt animal health-bolag. Bolaget som har sitt huvudkontor i USA kommer inom ramen f\u00f6r avtalet utv\u00e4rdera PharmaShell\u00ae\u00a0f\u00f6r en specifik kombinationsprodukt.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/","name":"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2018-12-17T07:45:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-ingar-avtal-med-varldsledande-animal-health-bolag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa ing\u00e5r avtal med v\u00e4rldsledande animal health-bolag"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}